Trial Profile

Phase IIa proof-of-concept trial of CC8464 in patients with Erythromelalgia

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs CC 8464 (Primary)
Indications Erythromelalgia
Focus Proof of concept; Therapeutic Use
Sponsors Channel Therapeutics Corporation

Most Recent Events

02 Jul 2025 According to a Pelthos Therapeutics media release, Channel Therapeutics Corporation has merged with Pelthos Therapeutics to form Pelthos Therapeutics.
21 Nov 2024 According to Chromocell Corporation media release, Chromocell Corporation has changed its name to Channel Therapeutics Corporation.
16 Feb 2024 According to a Chromocell Corporation media release, the net proceeds from the public offering will be used to prepare and begin conducting this trial.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com